261 filings
Page 9 of 14
8-K
uwl2cyb
7 Dec 17
Sage Therapeutics Reports PositiveTop-line Results from Phase 2 Placebo-Controlled Trial ofSAGE-217 in Major Depressive Disorder
12:00am
8-K
g6v8m6 nw42p3gyqp
17 Nov 17
Sage Therapeutics Announces Closing of $345 Million Public Offering of Common
12:00am
8-K
sfm87xjqhbheb0
15 Nov 17
Sage Therapeutics Announces Proposed Public Offering of Common Stock
12:00am
424B5
a50lvd wkt9h7jz4
15 Nov 17
Prospectus supplement for primary offering
12:00am
424B5
aut4jp1cgz7xr 0v26
13 Nov 17
Prospectus supplement for primary offering
12:00am
8-K
2pkdtrqwgb3n7l
9 Nov 17
Sage Therapeutics Announces Brexanolone Achieves Primary Endpoints in Both Phase 3 Clinical Trials in Postpartum Depression
12:00am
8-K
dy8zl5mc7f22x1j992jj
8 Nov 17
Departure of Directors or Certain Officers
12:00am
8-K
q776u9b36d4
7 Nov 17
Sage Therapeutics Announces Third Quarter 2017 Financial Results and Provides Pipeline Update
12:00am
8-K
3fno3
12 Sep 17
Sage Therapeutics ReportsTop-Line Results from Phase 3 STATUS Trial of Brexanolone in Super-Refractory Status Epilepticus
12:00am
8-K
3rhjn01 nh
3 Aug 17
Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update
12:00am
CT ORDER
88ouj
26 Jul 17
Confidential treatment order
12:00am
8-K
8d0188e
8 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
jypdrht0tqyxw9xdi
9 May 17
Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update
12:00am
DEFA14A
yg3nnsn sjg
28 Apr 17
Additional proxy soliciting materials
12:00am
8-K
s2xqbfg
9 Mar 17
Departure of Directors or Certain Officers
12:00am